Innovent Technologies is redefining the landscape of contract machining and manufacturing with precision, efficiency, and adaptability.

(RTTNews) - Innovent Biologics Inc. and HUTCHMED (China) Limited announced that the FRUSICA-2 Phase 2/3 clinical trial, which evaluated sintilimab in combination with fruquintinib as second-line ...

SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...

with potential positive implications for stakeholders in terms of market expansion and improved treatment solutions. More about Innovent Biologics Innovent Biologics, Inc. is a biopharmaceutical ...

Hong Kong-listed Innovent Biologics Inc. is considering a licensing partnership to develop a cancer drug that’s showing promise in treating several types of tumor, according to people familiar ...

Innovent Biologics (HK:1801) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with ...

HUTCHMED and Innovent Biologics announced that their FRUSICA-2 Phase II/III clinical trial of fruquintinib combined with sintilimab for the treatment of advanced renal cell carcinoma (RCC ...

As global markets grapple with inflation concerns and trade policy uncertainties, Asian tech stocks are capturing attention amid shifting economic dynamics. In this environment, identifying ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vaxcyte (PCVX – Research Report), Envista Holdings (NVST – Research Report) and Innovent ...